Registration Number
0225U000625,
(0123U101297)
, R & D reports
Title
To assess the effectiveness of adjuvant and neoadjuvant chemotherapy in muscle-invasive and non-muscle-invasive bladder cancer
popup.stage_title
Оцінити ефективність ад’ювантної та неоад’ювантної хіміотерапії при м’язево-інвазивному та м’язево-неінвазивному раку сечового міхура
Head
Sakalo Valerii S., Доктор медичних наук
Shuliak Oleksandr V., д.мед.н.
Registration Date
15-01-2025
Organization
State Institution "Academician O.F. Vozianov Institute of Urology of the National Academy of Medical Sciences of Ukraine"
popup.description1
To improve the results of treatment in patients with muscle-invasive and non-invasive bladder cancer with the justification of indications for the choice of organ-preserving surgical interventions with adjuvant chemoradiation therapy and with the determination of prognostic factors and the effectiveness of various schemes of intravesical chemotherapy.
popup.description2
The object of the study is patients with muscle-invasive and muscle-non-invasive bladder cancer. The aim of the study is to improve the immediate and long-term oncological results of treatment in patients with muscle-invasive and muscle-non-invasive bladder cancer by substantiating the indications for the choice of organ-preserving surgical interventions with adjuvant chemoradiotherapy. The object of the study - patients with muscle-invasive and muscle-non-invasive bladder cancer. Research methods - general clinical, sonographic, CT, pathomorphological, immunohistochemical. Results and novelty: When comparing the results of survival in patients with localized muscle-invasive bladder cancer stages T2a-T2bN0M0 after radical cystectomy, partial cystectomy + adjuvant radiation therapy and partial cystectomy + adjuvant polychemotherapy, comparable 5-year overall (51, 61±17.79%, 54.28±16.50%, 67.56±15.08%) and cancer-specific survival (54.83±17.52%, 54.28±16.50%, 64.86±15.39%), with slightly higher rates in organ-preserving treatment with adjuvant chemotherapy. According to the results of a retrospective study of bimodal (transurethral resection of bladder tumor with adjuvant chemotherapy) and trimodal therapy (transurethral resection of bladder tumor with adjuvant chemoradiation) compared with radical cystectomy for localized and locally advanced muscle-invasive bladder cancer. localized and locally advanced muscle-invasive bladder cancer (MIBC) stages T2a-N3bN0M0, the 5-year overall survival rate is 61, 1 %, 68,2 %, 75 %; tumor-specific survival - 66.7%, 72.2%, 75.0% and progression-free survival - 58.3%, 45.5%, 56.2%, no significant difference between the groups was found (p>0.05).
Product Description
popup.authors
Hatsereliia Zurab V.
Hryhorenko Viacheslav M.
Kosiukhno Maryna O.
Melnykov Serhii M.
Nehrei Larysa M.
Romashсhenko Oksana V.
Riabtseva Svitlana O.
Sakalo Anatolii V.
Sakalo Valerii S.
Shamraiev Serhii M.
Shuliak Oleksandr V.
popup.nrat_date
2025-01-15
